Quality and Affordable Health Care
"Like most Vermonters, I believe affordable access to quality health care is a fundamental right of all Americans. My work on this critical issue – in Vermont and now in Congress – has long been guided by three principles: everyone must be covered, everyone must contribute based upon his or her ability to pay, and coverage need not be related to employment. I will continue to push for comprehensive reform of our health care system to achieve quality, affordable care for all Vermonters and all Americans. And I will continue to bring Vermont’s values and successes in improving health care to the national stage."
Spotlight on Health Care
In November 2009, the House passed historic health care reform legislation. As a member of the Energy and Commerce Committee, Rep. Welch incorporated several Vermont ideas into the legislation. Rep. Welch helped author a provision of the bill to create a pilot program that promotes Accountable Care Organizations (ACOs), which rewards the quality and efficiency of care, rather than the volume and intensity of services. Building on these important reforms is necessary to reduce the rate at which health care costs are growing. He also successfully worked to allow young people through the age of 26 to remain on their parents’ health plans, and repeal the health insurance industry’s exemption from anti-trust regulations.
Today, Rep. Welch is continuing to fight to reduce health care costs, improve the quality of services, and increase access. He currently leads bills in the House that would expand the use of telehealth services, provide crucial support for rural health care providers, and reduce the cost of prescription drugs by requiring the federal government to negotiate prescription drug prices with pharmaceutical companies.
More on Quality and Affordable Health Care
WASHINGTON – Reps. Peter Welch (D-Vt.) and Francis Rooney (R-Fla.) sent a letter late Friday to federal regulators demanding scrutiny of the impact on consumers of the pending merger of two pharmaceutical giants, Celgene and Bristol-Myers Squibb.
WASHINGTON – Rep. Peter Welch (D-Vt.), Rep. Francis Rooney (R-Fla.) and nine House colleagues today introduced bipartisan legislation that would require the federal government to negotiate lower drug prices for seniors enrolled in the Medicare Part D program.
A divided Congress probably won’t be able to agree on much over the next two years. But that vacuum could bode well for one vexing problem both parties say they want to solve: the high cost of prescription drugs in the United States.
Hope is strong among health-care advocates and lawmakers that 2019 could be the year Congress and the executive branch finally make significant moves against the powerful prescription drug industry, after long acknowledging a need for action but doing little about it.
WASHINGTON, D.C. – This week, the House passed legislation introduced by Rep. Peter Welch (D-Vt.) that closes a loophole in the federal Medicaid program exploited by drug companies to minimize drug discounts required for participation in the program.
The Democratic takeover of the House is giving new life to efforts to fight high drug prices with bipartisan action, a worrying prospect for the pharmaceutical industry.
It’s a top priority for House Democrats, who now have powers to press the issue and put the drug industry on the hot seat. It’s also an issue where Democrats believe there is potential to reach a deal with President Trump.
Democrats celebrating their new-but-narrow control House majority are confronting a hard decision: Whether to work with the Trump administration – and the GOP-led Senate – to lower drug costs.
Rep. Peter Welch (D-Vt.), a lead sponsor of legislation in the House to mandate Medicare price negotiation, issued the following statement in reaction to President Trump’s announcement this afternoon on prescription drug pricing:
President Trump proposed on Thursday that Medicare pay for certain prescription drugs based on the prices paid in other advanced industrial countries — a huge change that could save money for the government and for millions of Medicare beneficiaries.
As part of a demonstration project covering half the country, Medicare would establish an “international pricing index” and use it as a benchmark in deciding how much to pay for drugs covered by Part B of Medicare.
WASHINGTON – In a White House ceremony this afternoon, President Trump signed into law a bipartisan package of opioid legislation, including four bills co-authored by Rep. Peter Welch (D-Vt.). While supporting the package, Welch decried the lack of a more comprehensive approach to combatting the opioid public health epidemic ravaging communities in Vermont and across the country.
Washington, DC – This afternoon, President Trump signed into law legislation co-authored by Rep. Peter Welch (D-Vt.) that eliminates so-called “gag rules” imposed on pharmacists that prevent them from steering their customers to the lowest cost option when filling a prescription.